On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) Launches Second Stage of Manufacturing of Ibogaine for Clinical Research

  • The company has filed patent applications for two routes of chemical synthesis of ibogaine – offering potential advantages of improved isomeric purity, chiral purity, and easily isolated intermediate compounds
  • Preliminary data indicates that the drug shows promise as a treatment for neuropathic pain and migraines, as well as the treatment of addiction
  • The company is positioned to engage several markets, including digital therapeutics and research

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (“MINDCURE”), a diversified life sciences company at the forefront of the mental health industry, recently announced the launch of its second manufacturing stage of pharmaceutical-grade ibogaine to be used in psychedelic clinical research. During this stage of manufacturing, the company will be assessing the quality of the synthetic ibogaine to be produced at scale to determine the timing and cost for commercial-scale manufacturing (https://nnw.fm/txKQO). 

Kelsey Ramsden, President and CEO of MINDCURE, spoke on the manufacturing goals stating, “We are now one step closer towards our goal of manufacturing synthetic ibogaine at a commercial scale for research purposes. We are currently working on proving the ability to scale up the production, and our next step will be to test the ibogaine to ensure it meets the highest standards of the pharmaceutical-grade product.”

Ibogaine is a psychoactive substance that can be found naturally in the roots of the African iboga tree. The company is actively researching ibogaine as a potential treatment for traumatic brain injury and other related conditions. All preliminary data show that the drug may also yield promising results as a treatment for neuropathic pain and migraines. In addition, research also indicates that ibogaine may help repair and rewire the brain’s neural pathways, making it potentially useful in the treatment of addiction.

MINDCURE has filed U.S. provisional patent applications for two routes of chemical synthesis of ibogaine. Both routes may provide advantages of improved isomeric purity, increased chiral purity, and more easily isolated intermediate compounds. Both are currently under assessment to determine the preferred method for further developing the compound (https://nnw.fm/iGTV9). 

Chief Medical Officer Joel Raskin discussed the natural iboga plant as a precious resource, stating, “Manufacturing synthetic ibogaine and patenting our process would create the opportunity for synthetic ibogaine to be used by researchers conducting clinical trials and, eventually, by clinicians providing psychedelic therapy. Our company’s research team would also have access to this sustainable drug supply.”

MINDCURE is positioned to disrupt several different market spaces through its technology, research, and products, including the digital therapeutics space, which covers health interventions delivered through a smart device to induce a behavioral change in the patient. The company’s leading foray into the digital therapeutics space is iSTRYM, an AI-driven software platform that enables personalized and calculated outcomes in psychedelic therapy. 

The global digital therapeutics market was valued at $2.88 billion in 2019, but it is expected to reach $13.8 billion by 2027 with a CAGR of 20.5% during the forecast period (https://nnw.fm/ZbdME). The global market for drug addiction therapy, where ibogaine can be a potential game changer, was valued at $17.65 billion in 2019 and is expected to grow at a CAGR of 7% during the forecast period, resulting in a value of $31.17 billion by 2027 (https://nnw.fm/D58Lf).

For more information, visit the company’s website at www.MindCure.com.

NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at https://nnw.fm/MCURF

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office

NetworkNewsWire is part of the InvestorBrandNetwork.


Select A Month

NetworkNewsWire Currently Accepts



Bitcoin Cash

Bitcoin Cash

Doge Coin






USD Coin

USD Coin

Contact us: 212.418.1217